The DNA microarray market is expected to reach $3.6 billion by 2006, driven largely by increasing adoption in the academic segment, greater throughput requirements in the pharmaceutical and biotechnology industries, and price reductions across all market segments.
The scanner and arrayer markets will exhibit the largest growth, each increasing at a compound annual growth rate (CAGR) of 44% to reach $1.64 billion and $887 million respectively, according to a new Strategic Market Report from Front Line Strategic Consulting.
DNA microarrays are powerful new tools for investigating the mechanism of many diseases and accelerating the drug development process, which can last upwards of 15 years.
While DNA microarrays will continue to be an essential tool for gene expression research, future applications will extend beyond the current pharmaceutical, biotechnology and academic user groups. By adopting microarrays in clinical diagnostics, physicians could detect genetic predispositions to specific diseases and customise treatment based on the patient’s genetic make-up, substantially reducing treatment costs and improving quality of care.
Currently, cost is the largest barrier for widespread application of DNA microarray technology; however, use should increase as prices decline over time. For example, growth in the integrated systems segment will occur at an average annual rate of 22%, driven by the price reduction of Affymetrix’s GeneChip system, as well as by an increased use of pre-fabricated arrays as they become more affordable.
Affymetrix dominates the arrayer market, and combined with Apogent and GeneMachines, comprise 73% of that market. The 44% CAGR forecasted for this segment by the new study reflects the purchase of replacement and upgraded instruments, as well as additional arrayers to support greater throughput.